The effects of antivirals with/without co-targeting the EGFR/ERK pathway on IL-6 protein expression in NB + 12 SMGs. mCMV infection (A) induces a notable increase in immunodetectable IL-6 in abnormal stromal cells. The addition of aciclovir beginning on day 6 (CMV + D6 Acy) (B) substantially reduces IL-6 immunostaining in stroma. When aciclovir was added beginning on day 6 to U0126-treated (CMV + U + D6 Acy) (C) or GEF-treated (CMV + GEF + D6Acy) (D) SMGs, the distribution of IL-6 immunostaining resembles control (compare C, D to 10 A, E), being detected in epithelia (e) and nerve cells (arrow) and absent from stroma. In contrast, IL-6 immunolocalization persists in stromal cells (arrowheads) in both U0126-treated SMGs treated with GEF beginning on day 6 (CMV + U + D6GEF) (E) or GEF-treated SMGs treated with U0126 beginning on day 6 (CMV+ GEF+ D6U) (F). Bar: A, B, F- 40 μm; C-E - 50 μm.